Novo Nordisk Arms Wegovy to Be a Triple Threat

Ozempic usage for weight loss has gone viral, making it the highest revenue-generating drug for Novo Nordisk AV/S NYSE: NVO. Originally purposed for Type 2 diabetes, the skyrocketing off-label use for weight loss led Novo to create Wegovy, a stronger version of Ozempic (generic name: semaglutide)…#novonordiskavsnyse #nvo #novo #ozempic #glp1 #elylillyco #lly #novonordisk #ejectionfraction #bmi
Source: Reuters: Health - Category: Consumer Health News Source Type: news